Opportunity Information: Apply for RFA AG 16 001
Apply for RFA AG 16 001
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "NIA Coordinating Center for Genetics and Genomics of Alzheimers Disease (U54)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866 Aging Research.
- This funding opportunity was created on Nov 25, 2014 and posted on Nov 25, 2014.
- Applicants must submit their applications by Jun 3, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,250,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $2,000,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Independent school districts Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities City or township governments Small businesses State governments Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled Additional Information on Eligibility for clarification) County governments Private institutions of higher education Public and State controlled institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The National Institute on Aging (NIA), part of the National Institutes of Health (NIH), issued this Funding Opportunity Announcement (RFA-AG-16-001) to fund a single Coordinating Center for the Genetics and Genomics of Alzheimer's Disease (CGAD) under a U54 cooperative agreement mechanism. The purpose of the award is to create a centralized hub that facilitates and supports the Replication Phase of the Alzheimer's Disease Sequencing Project (ADSP). In practical terms, the opportunity is aimed at building an organizing and technical backbone for large-scale genetics and genomics efforts that can reliably confirm (replicate) earlier findings, improve data comparability, and accelerate discovery that could eventually translate into prevention strategies or therapeutic avenues for Alzheimer's disease.
The CGAD is expected to act as the focal point for the ADSP replication phase, with an emphasis on joint data analysis, data harmonization, and data sharing across contributing projects and investigators. This means the coordinating center would not simply store data; it would actively enable combined analyses across multiple datasets, help align data formats and standards so results are comparable, and support efficient, responsible dissemination of information to the broader research community. The FOA positions the center as a national resource, underscoring that its deliverables are intended to serve the field beyond any one institution, including enabling collaborations and ensuring that replication-phase outputs are robust and useful to researchers working on Alzheimer's genetics and genomics.
Because this is a cooperative agreement, NIH involvement is typically more substantial than in a standard research project grant, reflecting the complexity and cross-cutting nature of coordination, governance, and shared infrastructure. The coordinating center is framed as supporting a major component of the full analytical range required in the ADSP replication phase, implying responsibilities that span from managing data inputs and quality control processes through to supporting multi-site analytical workflows, interpretive efforts, and the downstream sharing of results. The overall vision described is multidisciplinary, aligning with NIA programmatic needs and acknowledging that meaningful progress in Alzheimer's disease genomics depends on coordinated efforts across genetics, bioinformatics, statistics, epidemiology, data science, and related domains.
From a funding and administrative standpoint, the FOA anticipated one award, with an estimated total funding level of about $2,250,000 and an award ceiling of $2,000,000. No cost sharing or matching was required. The opportunity was posted on November 25, 2014, with an original and current closing date of June 3, 2015, and an archive date of July 4, 2015, indicating this specific competition is historical rather than currently open.
Eligibility was broad and included many common NIH-eligible organization types, such as public and private institutions of higher education, nonprofits (including 501(c)(3) entities and certain nonprofits without that status), for-profit organizations (other than small businesses), small businesses, and a range of government entities (state, county, city/township, special districts, independent school districts, and certain housing authorities). It also explicitly included several categories of institutions and organizations often highlighted in federal funding opportunities, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, and Asian American and Native American Pacific Islander Serving Institutions, as well as faith-based or community-based organizations and eligible federal agencies. At the same time, the FOA clearly restricted foreign involvement: non-U.S. entities and foreign institutions were not eligible to apply, non-U.S. components of U.S. organizations were not eligible, and foreign components were not allowed as defined by NIH policy.
Overall, this opportunity was designed to strengthen the reliability and impact of Alzheimer's disease genetic discovery by funding a central coordination and analytics resource for the ADSP replication phase. The key value proposition is infrastructure plus leadership: enabling large-scale replication studies to run smoothly across multiple contributors, standardizing and harmonizing complex genomics datasets, supporting rigorous joint analyses, and ensuring that high-value data and findings are shared in a way that meaningfully accelerates research toward prevention and treatment.
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This is a National Institute on Aging (NIA), National Institutes of Health (NIH) Funding Opportunity Announcement (FOA) identified as RFA-AG-16-001. It was issued to fund a single Coordinating Center for the Genetics and Genomics of Alzheimer's Disease (CGAD) under a U54 cooperative agreement mechanism.
Who is the sponsoring agency?
The sponsoring agency is the National Institute on Aging (NIA), which is part of the National Institutes of Health (NIH).
What does CGAD stand for?
CGAD stands for the Coordinating Center for the Genetics and Genomics of Alzheimer's Disease.
What is the primary purpose of the award?
The purpose is to create a centralized hub that facilitates and supports the Replication Phase of the Alzheimer's Disease Sequencing Project (ADSP). The center is intended to provide coordination, technical infrastructure, and leadership so large-scale replication efforts can be carried out reliably across multiple contributing projects and investigators.
What does the FOA mean by the "Replication Phase" of the ADSP?
Based on the FOA description, the Replication Phase focuses on confirming (replicating) earlier genetics and genomics findings. The goal is to strengthen confidence in results, improve comparability across datasets, and accelerate discovery that could eventually inform Alzheimer's disease prevention strategies or therapeutic avenues.
Is this award for conducting a single research project or for running a coordinating center?
This opportunity is specifically for running a coordinating center. The CGAD is expected to serve as an organizing and technical backbone for replication-phase efforts rather than operating as a simple data storage site or a single, stand-alone research project.
What are the core responsibilities of the CGAD under this FOA?
The CGAD is expected to act as the focal point for ADSP replication activities, with an emphasis on joint data analysis, data harmonization, and data sharing across contributing projects and investigators. The FOA frames the center as supporting a major portion of the analytical range needed for replication, spanning from managing data inputs and quality control through multi-site analytical workflows, interpretive support, and downstream sharing of results.
What is meant by "joint data analysis" in this context?
Joint data analysis refers to enabling combined analyses across multiple datasets and contributors so that replication-phase questions can be tested in a coordinated way, rather than in isolated silos. The FOA emphasizes that the coordinating center should actively enable these combined efforts.
What is meant by "data harmonization" in this context?
Data harmonization refers to aligning data formats, standards, and related practices so results are comparable across studies and datasets. The FOA highlights harmonization as a key expectation because replication studies rely on consistent handling of complex genomics data.
What is meant by "data sharing" in this context?
Data sharing, as described in the FOA, means supporting efficient and responsible dissemination of information to the broader research community. The CGAD is intended to help ensure replication-phase outputs are robust, useful, and accessible as a field-wide resource.
Is the CGAD intended to be a national resource?
Yes. The FOA positions the coordinating center as a national resource, emphasizing that deliverables are intended to serve the Alzheimer's genetics and genomics field beyond any single institution, including enabling collaborations and supporting broad utility of replication-phase outputs.
What award mechanism is used?
The FOA uses a U54 cooperative agreement mechanism.
What does it mean that this is a "cooperative agreement"?
The FOA indicates that NIH involvement is typically more substantial than in a standard research project grant. This reflects the complexity of coordination, governance, and shared infrastructure required for a cross-cutting coordinating center supporting multi-site efforts.
How many awards were anticipated?
The FOA anticipated a single award (one coordinating center).
How much funding was anticipated?
The FOA anticipated an estimated total funding level of about $2,250,000.
What was the award ceiling?
The award ceiling was $2,000,000.
Was cost sharing or matching required?
No. The FOA stated that no cost sharing or matching was required.
When was the opportunity posted?
The FOA was posted on November 25, 2014.
What was the application due date?
The original and current closing date listed in the FOA was June 3, 2015.
Is this FOA still open for applications?
No. The FOA information indicates it is historical. It has a closing date of June 3, 2015 and an archive date of July 4, 2015, which means this specific competition is not currently open.
What is the archive date, and what does it imply?
The archive date listed is July 4, 2015. In the context provided, this indicates the FOA has been archived and is not an active, open solicitation.
What types of organizations were eligible to apply?
Eligibility was broad and included many NIH-eligible organization types, including public and private institutions of higher education; nonprofit organizations (including 501(c)(3) entities and certain nonprofits without that status); for-profit organizations (other than small businesses); small businesses; and a range of government entities such as state, county, city/township, special districts, independent school districts, and certain housing authorities.
Were minority-serving institutions explicitly included as eligible?
Yes. The FOA explicitly included categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, and Asian American and Native American Pacific Islander Serving Institutions.
Are faith-based or community-based organizations eligible?
Yes. The FOA explicitly included faith-based or community-based organizations among eligible applicants, provided they otherwise meet NIH eligibility requirements.
Were federal agencies eligible to apply?
Yes. The FOA stated that eligible federal agencies were included among eligible applicant types.
Are foreign institutions eligible to apply?
No. The FOA clearly restricted foreign involvement: non-U.S. entities and foreign institutions were not eligible to apply.
Can a U.S. organization apply if it has a non-U.S. component?
No. The FOA specified that non-U.S. components of U.S. organizations were not eligible.
Are foreign components allowed in the project?
No. The FOA stated that foreign components were not allowed as defined by NIH policy.
What disciplines or expertise areas does the FOA suggest are relevant?
The FOA describes a multidisciplinary vision and notes that progress in Alzheimer's disease genomics depends on coordinated efforts across areas such as genetics, bioinformatics, statistics, epidemiology, data science, and related domains.
What is the overall value proposition of the CGAD according to the FOA?
The FOA frames the CGAD as "infrastructure plus leadership": enabling large-scale replication studies to run smoothly across multiple contributors, standardizing and harmonizing complex genomics datasets, supporting rigorous joint analyses, and ensuring that data and findings are shared in ways that accelerate research toward prevention and treatment.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01)
Previous opportunity: Alzheimers Disease Sequencing Project (ADSP) Replication Phase Analysis Studies (U01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AG 16 001
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AG 16 001) also looked into and applied for these:
| Funding Opportunity |
|---|
| Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01) Apply for RFA HL 16 006 Funding Number: RFA HL 16 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Sickle Cell Disease Newborn Screening Program Apply for HRSA 15 078 Funding Number: HRSA 15 078 Agency: Health Resources and Services Administration Category: Health Funding Amount: $2,679,000 |
| Alcohol Education Project Grants (R25) Apply for PAR 15 054 Funding Number: PAR 15 054 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Innovative Measures of Oral Medication Adherence for HIV Treatment and Prevention (R01) Apply for RFA AI 14 071 Funding Number: RFA AI 14 071 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improving Evaluation Capacity within the Government of Tanzania under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 1589 Funding Number: CDC RFA GH15 1589 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $3,500,000 |
| Partnering with Pasteur Institute of Ho Chi Minh City to Enhance Regional Capacity to Prevent, Detect, Monitor, and Respond to the HIV/AIDS Epidemic in Vietnam under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 1595 Funding Number: CDC RFA GH15 1595 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $4,000,000 |
| Statewide Family Network Program Apply for SM 15 001 Funding Number: SM 15 001 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $95,000 |
| Statewide Consumer Network Program Apply for SM 15 002 Funding Number: SM 15 002 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $95,000 |
| Service Area Competition Additional Areas (SAC AA) Green Valley, AZ Wichita, KS Franklin, NH Washington, NC and Cheyenne, WY Apply for HRSA 15 139 Funding Number: HRSA 15 139 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Human Cellular Models for Predicting Individual Responses to Cystic Fibrosis Transmembrane Conductance Regulator Directed Therapeutics (R41) Apply for RFA HL 15 026 Funding Number: RFA HL 15 026 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Human Cellular Models for Predicting Individual Responses to Cystic Fibrosis Transmembrane Conductance Regulator Directed Therapeutics (R43/R44) Apply for RFA HL 15 027 Funding Number: RFA HL 15 027 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| High Priority Immunology Grants (R01) Apply for PAS 15 055 Funding Number: PAS 15 055 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Perinatal and Infant Oral Health Quality Improvement Expansion Grant Program Apply for HRSA 15 070 Funding Number: HRSA 15 070 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Advanced Nursing Education Program Apply for HRSA 15 046 Funding Number: HRSA 15 046 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Unconventional Roles of Ethanol Metabolizing Enzymes, Metabolites, and Cofactors in Health and Disease (R21) Apply for PA 15 057 Funding Number: PA 15 057 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Unconventional Roles of Ethanol Metabolizing Enzymes, Metabolites, and Cofactors in Health and Disease (R01) Apply for PA 15 058 Funding Number: PA 15 058 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Clinical Trial or Biomarker Clinical Validation Study Cooperative Agreement (U01) Apply for PAR 15 059 Funding Number: PAR 15 059 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Predoctoral Training in General, Pediatric and Public Health Dentistry and Dental Hygiene Apply for HRSA 15 050 Funding Number: HRSA 15 050 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Asthma Empowerment Collaborations to Reduce Childhood Asthma Disparities (U01) Apply for RFA HL 17 001 Funding Number: RFA HL 17 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Epi Centers for the Prevention of Healthcare Associated Infections, Antimicrobial Resistance and Adverse Events A Multicenter Program Expansion (U54) Apply for RFA CK 11 0010501SUPP15 Funding Number: RFA CK 11 0010501SUPP15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $800,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AG 16 001", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.